biotech · Non-Small Cell Lung Cancer · Pneumococcal Vaccines · MAIA
MAIA Biotechnology
MAIA Biotechnology patent portfolio — 10 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- honolulu, USA
- Founded
- 2013
- Employees
- 5
- Programs
- 8
- Drugs
- 19
- Patents
- 10
MAIA Biotechnology patents
10 pharmaceutical patents indexed for MAIA Biotechnology. 0 expire within 24 months.
MAIA Biotechnology has 10 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12005069
Bortezomib compositions
granted -
US 11992514
Ready-to-use bivalirudin compositions
granted -
US 11918622
Ready-to-use bivalirudin compositions
granted -
US 11903993
Ready-to-use bivalirudin compositions
granted -
US 11752164
Bortezomib compositions
granted -
US 11737983
Storage stable sincalide formulations
granted -
US 11679119
Bortezomib compositions
granted -
US 11672813
Bortezomib compositions
granted -
US 11318100
Storage stable sincalide formulations
granted -
US 11110063
Storage stable sincalide formulations
granted
Frequently asked questions
How many patents does MAIA Biotechnology have?
10 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do MAIA Biotechnology patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.